Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150267 | 1.00 | CA9 (0.33) | CA9CA12CA1CA2ELANE | |
| SCHEMBL12858082 | 0.89 | ELANE (0.36) | ELANE | |
| SCHEMBL1150265 | 0.89 | ELANE (0.36) | ELANE | |
| SCHEMBL1149856 | 0.84 | — | — | |
| SCHEMBL7152812 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB | |
| SCHEMBL7154470 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB | |
| SCHEMBL8329413 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB | |
| SCHEMBL21510391 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB | |
| SCHEMBL8358880 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB | |
| SCHEMBL1266094 | 0.81 | TSHR (0.44) | CA9CA12CA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | CA9 4408/4885CA12 3970/4885CA1 2317/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | CA9 3606/4885CA12 1956/4885CA1 723/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | CA9 4151/4885CA12 4258/4885CA1 3771/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | CA9 4180/4885CA12 4254/4885CA1 3722/4885 |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | SCLY, SMOX, SMS | CA9 4408/4885CA12 3970/4885CA1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.